Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy

Hepatology

Volumn 32, Issue 5, 2000, Pages 1145-1153

  Suk Fong Lok, Anna ^a   Hussain, Munira ^a   Cursano, Carmela ^b   Margotti, Marzia ^b   Gramenzi, Annagiulia ^b   Luca Grazi, Gian ^b   Jovine, Elio ^b   Benardi, Mauro ^b   Andreone, Pietro ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA; VIRUS ENZYME;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; FEMALE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYBRIDIZATION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; STOP CODON; STRUCTURAL GENE; VIRUS GENOME; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0033754947     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.19622     Document Type: Article

References (33)

1. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
2. Lamivudine as initial treatment for chronic hepatitis B in the United States
3. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
4. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group
5. Lamivudine treatment for acute hepatitis B after liver transplantation
6. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
7. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
8. Three year lamivudine therapy in chronic HBV
9. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years
10. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group
11. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
12. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
13. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase
14. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)
15. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase
16. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme
17. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group
18. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
19. Features of response and resistance to lamivudine in patients with chronic hepatitis B with and without HBeAg
20. Liver transplantation in HBsAg-positive HBV-DNA-negative cirrhotics: Immunoprophylaxis and long-term outcome
21. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong
22. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion
23. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis
24. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes
25. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
26. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection
27. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
28. Antiviral chemotherapy for chronic hepatitis B infection: Lessons learned from treating HIV-infected patients
29. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B
30. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
31. Residual hepatitis B virus (HBV) infection in liver transplant patients under treatment with lamivudine (3TC): Assessment by quantiration of HBV DNA by PCR and assay of preS antigens
32. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy
33. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin